Literature DB >> 2606712

Biodistribution, dosimetry, metabolism and monkey PET studies of [18F]GBR 13119. Imaging the dopamine uptake system in vivo.

M R Kilbourn1, J E Carey, R A Koeppe, M S Haka, G D Hutchins, P S Sherman, D E Kuhl.   

Abstract

The in vivo characteristics of a new radiotracer, [18F]GBR 13119, have been examined. Full body biodistribution in rats has been determined and the expected human dosimetry calculated. Pharmacological specificity of in vivo regional brain distribution in rats was examined. Blockage of specific binding was accomplished by dopamine reuptake inhibitors but no effect was observed for pretreatment with serotonin or norepinephrine reuptake inhibitors. Preliminary examination of rat blood shows the presence of radiolabeled metabolites, which can be rapidly identified using bonded-phase (Sep-Pak) chromatography. Finally, the striatum of living primates has been imaged using PET and i.v. administration of [18F]GBR 13119. These results represent the intermediate steps in the development of [18F]GBR 13119 as a radiotracer for the study of the dopamine uptake system in man.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2606712     DOI： 10.1016/0883-2897(89)90072-x

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN： 0883-2897


  8 in total

1.  Fluorine-18 Radiolabeled PET Tracers for Imaging Monoamine Transporters: Dopamine, Serotonin, and Norepinephrine.

Authors:  Jeffrey S Stehouwer; Mark M Goodman
Journal:  PET Clin       Date:  2009-01

2.  [11C]NNC 12-0722 or [18F]GBR 13119: just what is "better"?

Authors:  M R Kilbourn
Journal:  Eur J Nucl Med       Date:  1994-07

Review 3.  Where have we got to with neuroreceptor mapping of the human brain?

Authors:  B Mazière; M Mazière
Journal:  Eur J Nucl Med       Date:  1990

4.  Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positron emission tomography studies and direct in vitro determinations.

Authors:  V Villemagne; J Yuan; D F Wong; R F Dannals; G Hatzidimitriou; W B Mathews; H T Ravert; J Musachio; U D McCann; G A Ricaurte
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

5.  Preparation of a potential positron emission tomographic radioligand for the dopamine transporter.

Authors:  L Müller; C Halldin; C Foged; P Karlsson; H Hall; C G Swahn; P D Suzdak; R Hohlweg; E B Nielsen; L Farde
Journal:  Eur J Nucl Med       Date:  1994-02

6.  Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease.

Authors:  R B Innis; J P Seibyl; B E Scanley; M Laruelle; A Abi-Dargham; E Wallace; R M Baldwin; Y Zea-Ponce; S Zoghbi; S Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 7.  A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909.

Authors:  R B Rothman; J R Glowa
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

8.  Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC).

Authors:  Isaac M Jackson; So Jeong Lee; Alexandra R Sowa; Melissa E Rodnick; Laura Bruton; Mara Clark; Sean Preshlock; Jill Rothley; Virginia E Rogers; Leslie E Botti; Bradford D Henderson; Brian G Hockley; Jovany Torres; David M Raffel; Allen F Brooks; Kirk A Frey; Michael R Kilbourn; Robert A Koeppe; Xia Shao; Peter J H Scott
Journal:  EJNMMI Radiopharm Chem       Date:  2020-11-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.